about
Rib plating of acute and sub-acute non-union rib fractures in an adult with cystic fibrosis: a case reportLung transplantation for cystic fibrosisYear-to-year changes in lung function in individuals with cystic fibrosis.Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis.Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis.Toxicity effects of short term diesel exhaust particles exposure to human small airway epithelial cells (SAECs) and human lung carcinoma epithelial cells (A549).Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry.The Dynamics of Disease Progression in Cystic Fibrosis.Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutationLung transplantation and survival in children with cystic fibrosisImproving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium.Pediatric lung transplantation for cystic fibrosis.Genetic discovery, rigorous statistics, and pandemic influenza.Use of lung transplantation survival models to refine patient selection in cystic fibrosis.Use of older donors for lung transplantation-you can't get there from here.A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.Selection of patients with cystic fibrosis for lung transplantation.Population Pharmacokinetics of Amikacin in Adult Patients with Cystic FibrosisMicrobial Interactions in the Cystic Fibrosis AirwayDesign of the REVEAL Registry for US Patients With Pulmonary Arterial HypertensionNonisotropic enzyme--inhibitor interactions: a novel nonoxidative mechanism for quantum proteolysis by human neutrophilsLung transplantation for cystic fibrosisTesting lung function decline to time lung transplantationEpidemiology of cystic fibrosis-related diabetesCarrier screening, incidence of cystic fibrosis, and difficult decisionsMeasurement of lung volumesSpirometryAdolescents with cystic fibrosis: take the door, not the windowThailandamide, a Fatty Acid Synthesis Antibiotic That Is Coexpressed with a Resistant Target GeneA multi-scale approach to study biochemical and biophysical aspects of resveratrol on diesel exhaust particle-human primary lung cell interactionRefinement of metabolite detection in cystic fibrosis sputum reveals heme correlates with lung function declineHigh-mobility group box-1 increases epithelial sodium channel activity and inflammation via the receptor for advanced glycation end products
P50
Q21199568-6D88196B-E850-4AAB-AC07-899CF727D636Q28749501-1857E7EC-C5CF-45D0-BCAA-70DFB2E8A379Q33918035-618141E7-E33F-41D0-8ADC-20C9EC45BCD1Q34390999-1B5E232E-287A-405F-B622-245ADFD12F56Q34416814-876111F8-EE09-4CB1-B007-7A786299C365Q34466259-B79591FF-9F7D-4DB4-8727-DB39BF7A5A2BQ35410804-94FFA4E1-AE7D-4290-BA2A-431C3A793C5CQ36036190-C5F9D7BA-01BD-4F10-9D6C-6729DD78F5AEQ36212667-E168496D-7A36-4B0A-BE4F-D77ACE0C09FFQ36848748-DC8E2423-250A-4648-9D5E-BE471B492DA8Q36860528-971CE7D8-0782-4C22-A733-0387FE791326Q42033824-D145C61B-F0B2-48E5-9D5D-ECE8C0EA0A80Q42617694-37D24940-5ED5-4564-B5D4-10FDE65DF39CQ42647223-DFCA1885-8A08-4527-9F9C-71C39C015FCDQ43810018-04A2DDB2-0FEB-469A-9FC6-7405BD5E8DFEQ46880557-603E56CC-1F91-4293-A4F0-159BE454AB21Q48385253-FAEF5C35-263D-41D5-8F0E-C4F0B10115D0Q51700104-E23EB17D-592E-4B1B-8DD5-81F0DBF9C788Q57151052-A6BF33D2-EFFE-4708-BCAE-2696CF76C665Q57174565-8504FBAC-7F0D-40E4-8DB0-412D737D7EB3Q58485984-3B92A759-8427-4587-8B5C-4A3E2BDDFD6FQ70782857-3047ADB1-6812-4A4B-A884-DD303963737CQ79279460-9B9A8378-683F-4F68-B750-170E5D42E241Q80345602-DC9AF6C8-0382-4586-BBFB-C0542E0C0C1CQ81713930-FD33CE8C-2965-436C-9B8A-34A901AB6927Q82238230-950519C6-E8F5-4A82-AF51-F9AAEBD7BAAAQ83593939-D9882278-0957-4539-A67D-CF684F0F9D8BQ83612383-888EAD21-3E89-4340-BC30-DCFDAD916070Q86596586-49A0D7A6-68AB-439E-81B3-F3FFFE406740Q89143122-4784139E-FE39-4D57-A622-48375755DA1EQ91656731-9E90B7C8-CB8A-472C-8035-B9DEF0A34C96Q92085747-B3C60672-DB22-4477-9E5A-7ECA1B82F695Q92493852-4320637A-7EAD-4DE7-A554-ADFA43AE261F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Theodore G Liou
@nl
Theodore G Liou
@sl
Theodore G. Liou
@en
Theodore G. Liou
@es
type
label
Theodore G Liou
@nl
Theodore G Liou
@sl
Theodore G. Liou
@en
Theodore G. Liou
@es
prefLabel
Theodore G Liou
@nl
Theodore G Liou
@sl
Theodore G. Liou
@en
Theodore G. Liou
@es
P106
P1153
57189048235
7102042374
P31
P496
0000-0003-0121-4847